Bayer

Bayer’s Trio of Headlines: A Closed Biotech Deal, a Trade Probe, and a Roundup Setback for Plaintiffs

kashif hafeez -

Bayer’s Big-Ticket Eye-Drug Wager Divides Institutional Money as Legal Clouds Gather

Bayer Recasts Its Leadership as Pharma Pipeline Starts to Deliver

Brett Shapiro -

Bayer Holds a Thin Line Above a 200-Day Floor as Industry Pullbacks and a CEO’s Warnings Converge

Brett Shapiro -

Bayer Faces Make-or-Break Court Ruling as FDA Fast Tracks Two Drugs and Cash Burn Deepens

kashif hafeez -

Bayer’s Q1 Smashes Forecasts as Crop Science Rebounds, But Glyphosate Cloud Remains

angelina -

Bayer’s Legal Tightrope: Supreme Court Showdown Meets a €7 Billion Capital Cushion

Bayer’s Dividend Stays at Minimum as Supreme Court Glyphosate Hearing Looms

angelina -

Bayer Faces a Week of Reckoning as Supreme Court, Shareholders, and Lobbying Scrutiny Converge

Bayer’s Clinical Pipeline and Factory Innovation Face Off Against a Mountain of Debt

angelina -

Bayer’s Legal and Financial Tightrope Walk Enters Critical Phase

Bayer’s Stroke Drug Breakthrough Validates Turnaround Strategy

Brett Shapiro -

Bayer’s Pivotal Quarter: Legal Battles and Leadership Shifts Shape the Path Forward

Brett Shapiro -

Trade Tensions Cast Shadow Over Bayer’s Pharmaceutical Ambitions

kashif hafeez -

FDA Approval of Lynkuet Marks Strategic Milestone for Bayer

Brett Shapiro -
123Page 2 of 3